Oncology & Cancer

The right combination: Overcoming drug resistance in cancer

Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed ...

Oncology & Cancer

Skp2 activates cancer-promoting, glucose-processing Akt

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

Oncology & Cancer

Latest research confirms genetic susceptibility to lung cancer

Previous research has shown that Asian patients with lung cancer are more likely to harbor epidermal growth factor receptor (EGFR) mutations. Furthermore, Asian patients with lung cancer are more likely to be non-smokers ...

Oncology & Cancer

Vandetanib doesn't up survival in non-small-cell lung cancer

(HealthDay) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 in the Journal of ...

page 11 from 15